Suppression of MD2 inhibits breast cancer in vitro and in vivo

Zheng, Shaoling; Fu, Weida; Ma, Ruimin; Huang, Qidi; Gu, Junwei; Zhou, Jieyu; Lu, Kangkang; Guo, Gui-Long

doi:10.1007/s12094-021-02587-9

Cited by 5 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies obtained similar results in gastric cancer ( Zhang et al, 2017 ), colon cancer ( Rajamanickam et al, 2020 ), and hepatocellular cancer ( Qi et al, 2021 ). However, LY96 was downregulated in breast cancer, and LY96 suppression can inhibit cancer development both in vivo and in vitro ( Zhang et al, 2017 ; Zheng et al, 2021 ), which was inconsistent with our result. These conflicting results may be a reflection of patients with a genetic background or molecular type in breast cancer.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Pan-Cancer Analysis of the Characteristics of LY96 in Prognosis and Immunotherapy Across Human Cancer

Nie

Peng

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Lymphocyte antigen 96 (LY96) is implicated in tumorigenesis by modulating host immunity. However, an integrated pan-cancer analysis of LY96 in prognosis and immunotherapy across human cancers is still lacking. Therefore, we analyzed the LY96 expression and its prognostic role in tumors by multiple databases. We also investigated the correlation between LY96 and copy number, DNA methylation, somatic mutation, microsatellite instability (MSI), tumor mutation burden (TMB), tumor microenvironment (TME), and immune cell infiltration across human cancers. In addition, the biological processes related to LY96 across various tumors and the correlation between LY96 and 50% inhibitive concentration (IC50) of various drugs were investigated. We found that LY96 was differently expressed between tumor and normal tissues and was significantly upregulated in most types of cancers. LY96 was gradually upregulated from stages I to IV in several cancers. Moreover, we found LY96 may play a prognostic role in most cancers, and patients with high or low LY96 expression often show different clinical outcomes. LY96 was also associated with copy number, DNA methylation, somatic mutation, MSI, TMB, TME characteristics, and immune cell infiltration in cancers. LY96 may also regulate classic tumor-associated pathways in several cancers and is related to drug resistance. This article may help to elucidate the role of LY96 in tumorigenesis, which may promote the development of immunotherapy and targeted therapy in cancers.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…Qi et al found that suppression LY96 prevents the migration and invasion of hepatocellular carcinoma cells ( Qi et al, 2021 ). Zheng et al found LY96 silence inhibit migration and invasion of breast cancer cells ( Zheng et al, 2021 ). Furthermore, we analyzed the prognostic role of LY96 across 33 types of cancer.…”

Section: Discussionmentioning

confidence: 99%

Pan-Cancer Analysis of the Characteristics of LY96 in Prognosis and Immunotherapy Across Human Cancer

Nie

Peng

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…By contrast, the roles of the coreceptor of TLR4, MD2, in tumor progression remain poorly understood. Although MD2 has been reported to be overexpressed in breast cancer and colon cancer cells to promote proliferation, migration and invasion of tumor cells in recent years ( 57 – 59 ), the expression of MD2, its association with tumor progression and its functional roles in gliomas are unclear. In the present study, MD2 was proved to serve as an independent prognostic factor to predict overall survivals of glioma patients.…”

Section: Discussionmentioning

confidence: 99%

MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas

Zhao

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundGlioma is the most common primary malignant tumor in the central nervous system. Myeloid differentiation protein 2 (MD2) acts as a coreceptor of toll-like receptor 4 (TLR4) to mediate innate immune response. However, the actual roles of MD2 in the regulation of progression and immune cell infiltration in gliomas remain largely unclear. This study aims to explore whether MD2 could be an independent prognostic factor through the mediation of immune cell infiltration in gliomas.MethodsThe mRNA expression and DNA methylation differential analyses of MD2 were performed using CGGA, TCGA and Rembrandt databases and survival analyses were performed using Kaplan-Meier plotter. Univariate and multivariate Cox regression was applied to analyze the prognostic value of MD2 and nomograms were constructed to evaluate the clinical value of MD2. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were utilized to analyze MD2-related signal pathways. Furthermore, correlations between MD2 and immune cell infiltration were calculated by TIMER and CIBERSOPT. The correlation between MD2 expression and the infiltrations of macrophages and neutrophils was experimentally verified by the knockdown of MD2 expression using small interfering RNA (siRNA) in glioma cells.ResultsWe found that MD2 was overexpressed and associated with a poor prognosis in gliomas. Meanwhile, higher expression of MD2 could be a result of lower DNA methylation of MD2 gene in gliomas. In addition, univariate and multivariate Cox regression analysis indicated that MD2 could be an independent prognostic factor for gliomas. Further functional enrichment analysis revealed that the functions of MD2 were closely related to immune responses. Moreover, the expression level of MD2 was strongly correlated with the infiltration and polarization of pro-tumor phenotype of tumor-associated macrophages and tumor-associated neutrophils in gliomas.ConclusionsThese findings have provided strong evidence that MD2 could be served as a valuable immune-related biomarker to diagnose and predict the progression of gliomas.

show abstract

“…Two cell models, the human breast cancer cell line (MDA-MB-231) and murine breast cancer cell line (4T1), were selected for this experiment. The MDA-MB-231 was grown according to the culture conditions recommended in the literature [ 22 ]. MDA-MB-231 was cultured using DMEM medium containing 10% fetal bovine serum in a 37 °C, 5% CO 2 incubator.…”

Section: Methodsmentioning

confidence: 99%

Highly Biocompatible Apigenin-Loaded Silk Fibroin Nanospheres: Preparation, Characterization, and Anti-Breast-Cancer Activity

Han

et al. 2022

Polymers

View full text Add to dashboard Cite

Breast cancer is among the most common fatal diseases among women. Low-toxicity apigenin (AGN) is of interest due to its good antitumor activity, but its clinical application is severely limited due to its poor water solubility and low bioavailability. An effective strategy to enhance the anti-breast-cancer activity of AGN is to develop it as a nanodelivery system. Silk fibroin (SF) is an ideal drug carrier with good biocompatibility, biodegradability, and a simple extraction process. This paper develops a novel and efficient apigenin-loaded silk fibroin nanodelivery system (SF-AGN) by nanoprecipitation with SF as a carrier. The system was characterized in terms of morphology, zeta potential, particle size, ultraviolet (UV), infrared (IR), and synchronous thermal analyses (TG-DSC), and the in vitro cytotoxicity and in vivo pharmacokinetics were examined. Finally, the chronic toxicity of SF-AGN in mice was studied. The SF-AGN nanodelivery system has good dispersibility, a hydrated particle size of 163.35 nm, a zeta potential of −18.5 mV, an average drug loading of 6.20%, and good thermal stability. MTT studies showed that SF-AGN significantly enhanced the inhibitory effect of AGN on 4T1 and MDA-MB-231 cells. Pharmacokinetic studies have demonstrated that SF-AGN can dramatically improve the bioavailability of AGN. The results of toxicity experiments showed that SF-AGN is biocompatible and does not alter normal tissues or organs. In sum, the SF-AGN nanodelivery system is a promising drug-delivery system for the clinical treatment of breast cancer.

show abstract

Suppression of MD2 inhibits breast cancer in vitro and in vivo

Cited by 5 publications

References 20 publications

Pan-Cancer Analysis of the Characteristics of LY96 in Prognosis and Immunotherapy Across Human Cancer

Pan-Cancer Analysis of the Characteristics of LY96 in Prognosis and Immunotherapy Across Human Cancer

MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas

Highly Biocompatible Apigenin-Loaded Silk Fibroin Nanospheres: Preparation, Characterization, and Anti-Breast-Cancer Activity

Contact Info

Product

Resources

About